drugset / Trial / NCT07017179

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

NCT07017179

Phase 2 Active not recruiting 14 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.

Timeline

Start
2025-05-20
Primary completion
2026-08-06
Completion
2026-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6234 Small activating RNA (saRNA) Subcutaneous
Subject AZD9550 Other / unclassified Subcutaneous

Indications